Showing 796 results
- Media Release /New data show that 73% of ankylosing spondylitis (AS) patients taking Cosentyx® (secukinumab) achieved improvement in AS signs and symptoms at four years, with sustained ASAS response rates1 AS is a…
- Media Release /- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis,…
- Media Release /Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
- Media Release /- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2…
- Media Release /-- Kymriah was the first CAR-T cell therapy to ever be approved by a regulatory authority-- Since 1970, more than 40 Novartis innovative therapies have been recognized by the Prix Galien Foundation…
- Media Release /- Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation- Approval based…
- Media Release /- 2018 STEP Program™ designed to support unique proposals from nonprofit organizations that serve people living with sickle cell disease- Novartis will select proposals that demonstrate innovation in…
- Media Release /-New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients-Crizanlizumab, a monthly infusion…
- Media Release /- BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after…
- Media Release /- Promacta (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic…
Pagination
- ‹ Previous page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- …
- 80
- › Next page